{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:32:48Z","timestamp":1790839968481,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,6,24]],"date-time":"2012-06-24T00:00:00Z","timestamp":1340496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tumour necrosis factor\u2010alpha (<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>) is an important mediator of the molecular cascade leading to chronic inflammation.<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>inhibitors have proven their safety and efficacy in the treatment of inflammatory diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review the non\u2013malignant haematological adverse events, such as thrombocytopaenia, neutropaenia, hypercoagulability, pancytopaenia and aplastic anaemia in patients receiving<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed the literature by searching<jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>databases as well as references of all retrieved articles for the following terms: anti\u2010tumour necrosis factor, anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>, infliximab, adalimumab, certolizumab, etanercept, haematological complications, thrombocytopaenia, neutropaenia, anaemia, bone marrow and thrombosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thombocytopaenia is a very rare phenomenon and was associated with no serious adverse events. However, transient neutropaenia developed in up to 16% of cases. Patients with a previous history of neutropaenia on other therapies or baseline neutrophil count &lt;4\u00a0\u00d7\u00a010<jats:sup>9<\/jats:sup>\/L are at a particularly higher risk. The association between anti\u2010<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>therapy and thrombosis is very nebulous due to the multitude of potential confounders. Only one case of primary eosinophilia has been reported with anti\u2010<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Regular monitoring of the white blood cell count at baseline and with each infusion is recommended for patients on anti\u2010<jats:styled-content style=\"fixed-case\">TNF\u2010\u03b1<\/jats:styled-content>. Further studies to elucidate their interaction with the immune system are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05189.x","type":"journal-article","created":{"date-parts":[[2012,6,25]],"date-time":"2012-06-25T11:54:56Z","timestamp":1340625296000},"page":"312-323","source":"Crossref","is-referenced-by-count":80,"title":["Review article: non\u2010malignant haematological complications of anti\u2010tumour necrosis factor alpha therapy"],"prefix":"10.1111","volume":"36","author":[{"given":"T.","family":"Bessissow","sequence":"first","affiliation":[{"name":"Department of Gastroenterology University Hospital Gasthuisberg Leuven Belgium"},{"name":"Department of Gastroenterology Royal Victoria Hospital, McGill University Health Center Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Renard","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rutgeerts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Van Assche","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.168"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.003"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.001"},{"key":"e_1_2_6_7_1","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor\u2010alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_1","first-page":"2315","article-title":"Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor\u2010\u03b1 antagonists in patients with rheumatoid arthritis?","volume":"30","author":"Ang HT","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023473"},{"issue":"1","key":"e_1_2_6_10_1","first-page":"111","article-title":"TNF\u2010alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis","volume":"12","author":"Jacobsen SE","year":"1994","journal-title":"Stem Cells"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70211-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902784162"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.06.005"},{"key":"e_1_2_6_14_1","first-page":"280","article-title":"Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor\u2010a inhibitors","volume":"10","author":"Chen M","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.001"},{"key":"e_1_2_6_16_1","unstructured":"Data on file Crohn's Disease Integrated Summary of Safety Abbott Montreal Canada."},{"key":"e_1_2_6_17_1","unstructured":"Data on file Rheumatoid Arthritis Integrated Summary of Safety Abbott Montreal Canada."},{"key":"e_1_2_6_18_1","unstructured":"Data on file (S_AE_63_D2 2006) Janssen Biotech Inc. Horsham PA USA."},{"key":"e_1_2_6_19_1","unstructured":"Data on file (ISS; pages 134\u2013136 2005) Centocor Inc. Horsham PA USA."},{"key":"e_1_2_6_20_1","unstructured":"Data on file (Protocol C0168T47; 2004) Janssen Biotech Inc. Horsham PA USA."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00033"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0229-y"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006775"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel204"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.123547"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2008.01.011"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2340\/00015555-0400","article-title":"Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis","volume":"88","author":"Stinco G","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069484"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630902936802"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22989"},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"208e14","DOI":"10.1186\/ar1803","article-title":"Primary and secondary autoimmune neutropenia","volume":"7","author":"Capsoni F","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.4.369"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1128\/iai.62.7.2779-2783.1994","article-title":"Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection","volume":"62","author":"Sj\u00f6stedt A","year":"1994","journal-title":"Infect Immun"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3219"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H"},{"key":"e_1_2_6_37_1","first-page":"247","article-title":"Drug\u2010induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy","volume":"23","author":"Favalli EG","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056176"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0187-3"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0415-y"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem332"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0436-0"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.09.017"},{"key":"e_1_2_6_45_1","first-page":"643","article-title":"Serious neutropenia following Etanercept administration in a 62\u00a0years female patient of rheumatoid arthritis","volume":"58","author":"Datta K","year":"2010","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20037"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21466"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1822-2"},{"key":"e_1_2_6_49_1","first-page":"257","article-title":"Standardization of definitions and criteria for causality assessment of adverse drug reaction. Drug\u2010induced blood cytopenias: report of an international consensus meeting","volume":"33","author":"Benichou C","year":"1993","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"key":"e_1_2_6_50_1","unstructured":"British Society of Rheumatology on safety of anti\u2010TNF therapies. Available at:http:\/\/www.rheumatology.org.uk\/includes\/documents\/cm_docs\/2010\/r\/ra_guidelines_on_safety_of_antitnf_therapies_sept_2010.pdf. Accessed June 12 2012."},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04026.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1995.1003"},{"key":"e_1_2_6_53_1","first-page":"269","article-title":"Beneficial effect of treatment with a monoclonal anti\u2010tumor necrosis factor\u2010alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease","volume":"27","author":"Hommes DW","year":"1997","journal-title":"Haemostasis"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6.1531"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2003.09.004"},{"key":"e_1_2_6_56_1","first-page":"S373","article-title":"Development of ACLA (anti\u2010cardiolipin antibodies) in patients treated with infliximab (remicade)","volume":"44","author":"Jonsdottir T","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30209"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R600021-JLR200"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20371"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00039.x"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00010"},{"key":"e_1_2_6_62_1","first-page":"679","article-title":"Occurrence of pulmonary thromboembolism during infliximab therapy","volume":"21","author":"Eklund KK","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07368.x"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.018515"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200409000-00022"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(04)95017-8"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh451"},{"key":"e_1_2_6_68_1","first-page":"546","article-title":"Arterial thrombosis with anti\u2010phospholipid antibodies induced by infliximab","volume":"17","author":"Nosbaum A","year":"2007","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f376ac"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep270"},{"key":"e_1_2_6_71_1","first-page":"355","article-title":"Arterial and venous thromboembolic events during anti\u2010TNF therapy: a study of 85 spontaneous reports in the period 2000\u20132006","volume":"19","author":"Petitpain N","year":"2009","journal-title":"Biomed Mater Eng"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04526.x"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-4-12"},{"key":"e_1_2_6_74_1","first-page":"78","article-title":"Peripheral arterial thrombosis following administration of infliximab for Crohn disease","volume":"10","author":"Mehta Shameer J","year":"2010","journal-title":"Grand Rounds"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492011000300015"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2011.00620.x"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21397"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318231fd99"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00115.x"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1159\/000080075"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg341"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key051"},{"key":"e_1_2_6_84_1","unstructured":"Ben SalemC et\u00a0al.Infliximab\u2010induced bone marrow aplasis and vasculitis 9th Annual Meeting of the International Society of Pharmacovigilance Abstr. 10 Reims France 6 October 2009."},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0691-8"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070741"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00701-7"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(05)83984-3"},{"key":"e_1_2_6_89_1","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis","volume":"30","author":"Ramanan AV","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.01.011"},{"key":"e_1_2_6_91_1","first-page":"248","article-title":"Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept","volume":"21","author":"Cancelliere N","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_6_92_1","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.14309\/00000434-200509001-00592","article-title":"Pulmonary eosinophilia associated with infliximab treatment of Crohn's disease","volume":"100","author":"Rubin DT","year":"2005","journal-title":"Ame J Gastroenterol"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker322"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.01.021"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02165.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05189.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05189.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T14:08:39Z","timestamp":1743602919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05189.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,24]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05189.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05189.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,24]]}}}